GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Crescent Biopharma Inc (NAS:CBIO) » Definitions » FCF Yield %

CBIO (Crescent Biopharma) FCF Yield % : -2.01 (As of Jun. 29, 2025)


View and export this data going back to 2025. Start your Free Trial

What is Crescent Biopharma FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Crescent Biopharma's Trailing 12-Month Free Cash Flow is $-6.27 Mil, and Market Cap is $312.00 Mil. Therefore, Crescent Biopharma's FCF Yield % for today is -2.01%.

The historical rank and industry rank for Crescent Biopharma's FCF Yield % or its related term are showing as below:

CBIO' s FCF Yield % Range Over the Past 10 Years
Min: -20291900   Med: 0   Max: 6399700
Current: -2.01

During the past 1 years, the highest FCF Yield % of Crescent Biopharma was 6399700.00%. The lowest was -20291900.00%. And the median was 0.00%.

CBIO's FCF Yield % is ranked better than
76.25% of 1499 companies
in the Biotechnology industry
Industry Median: -13.44 vs CBIO: -2.01

Crescent Biopharma's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.

Crescent Biopharma FCF Yield % Historical Data

The historical data trend for Crescent Biopharma's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Crescent Biopharma FCF Yield % Chart

Crescent Biopharma Annual Data
Trend Dec24
FCF Yield %
-

Crescent Biopharma Quarterly Data
Dec24
FCF Yield % -

Competitive Comparison of Crescent Biopharma's FCF Yield %

For the Biotechnology subindustry, Crescent Biopharma's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Crescent Biopharma's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Crescent Biopharma's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Crescent Biopharma's FCF Yield % falls into.


;
;

Crescent Biopharma FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Crescent Biopharma's FCF Yield % for the fiscal year that ended in Dec. 2024 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=0 /
=N/A%

Crescent Biopharma's annualized FCF Yield % for the quarter that ended in Dec. 2024 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-6.269 * 4 / 0
=N/A%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crescent Biopharma FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Crescent Biopharma FCF Yield % Related Terms

Thank you for viewing the detailed overview of Crescent Biopharma's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Crescent Biopharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Crescent Biopharma Inc (NAS:CBIO) » Definitions » FCF Yield %
Comparable Companies
Traded in Other Exchanges
N/A
Address
221 Crescent Street, Suite 105, Building 23, Waltham, MA, USA, 02453
Website
https://www.crescentbiopharma.com
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.